Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors

References

• Barar J, Rafi MA, Pourseif MM, et al. Blood-brain barrier transport machineries and targeted therapy of brain diseases. BioImpacts. 2016;6:225–248.
   PubMed Web of Science ®Google Scholar
• Stock AD, Gelb S, Pasternak O, et al. The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface. Autoimmun Rev. 2017;16:612–619.
   PubMed Web of Science ®Google Scholar
• Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8:1481–1493.
   PubMed Web of Science ®Google Scholar
• Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des. 2014;20:1422–1449. Epub 2013 Jun 25.
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez SH, Haorah J, et al. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1:223–236.
   PubMed Web of Science ®Google Scholar
• Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr Neuropharmacol. 2008;6:179–192.
   PubMed Web of Science ®Google Scholar
• Martin-Padura I, Lostaglio S, Schneemann M, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998;142:117–127.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Mariscal L, Betanzos A, Nava P, et al. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1–44.
   PubMed Web of Science ®Google Scholar
• Johnsen KB, Burkhart A, Melander F, et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;7:10396.
   PubMed Web of Science ®Google Scholar
• McConnell HL, Kersch CN, Woltjer RL, et al. The translational significance of the neurovascular unit. J Biol Chem. 2017;292:762–770. Epub 2016 Dec 7.
   PubMed Web of Science ®Google Scholar
• Muoio V, Persson PB, Sendeski MM. The neurovascular unit – concept review. Acta Physiol. 2014;210:790–798. Epub 2014 Mar 19.
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173–185. Epub 2005 May 26.
   PubMed Web of Science ®Google Scholar
• Baeten KM, Akassoglou K. Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke. Dev Neurobiol. 2011;71:1018–1039. Epub 2011 Jul 23.
   PubMed Web of Science ®Google Scholar
• Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123:4195–4200. Epub 2010 Dec 3.
   PubMed Web of Science ®Google Scholar
• Kowianski P, Lietzau G, Steliga A, et al. The astrocytic contribution to neurovascular coupling – still more questions than answers? Neurosci Res. 2013;75:171–183. Epub 2013 Feb 20.
   PubMed Web of Science ®Google Scholar
• Mahmoud S, Gharagozloo M, Simard C, et al. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells. 2019;8:1–27.
   Web of Science ®Google Scholar
• Weber B, Barros LF. The astrocyte: powerhouse and recycling center. Cold Spring Harb Perspect Biol. 2015;7:1–15.
   Web of Science ®Google Scholar
• Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7:452–464. Epub 2005 Oct 11.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13–25. Epub 2009 Aug 12.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. Neurorx. 2005;2:3–14. Epub 2005 Feb 18.
   PubMedGoogle Scholar
• Vorbrodt AW, Dobrogowska DH. Molecular anatomy of intercellular junctions in brain endothelial and epithelial barriers: electron microscopist’s view. Brain Res Brain Res Rev. 2003;42:221–242. Epub 2003 Jun 7.
   PubMed Web of Science ®Google Scholar
• Omidi Y, Barar J. Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts. 2012;2:5–22.
   PubMedGoogle Scholar
• Gynther M, Laine K, Ropponen J, et al. Large neutral amino acid transporter enables brain drug delivery via prodrugs. J Med Chem. 2008;51:932–936. Epub 2008 Jan 26.
   PubMed Web of Science ®Google Scholar
• Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents. 2003;22:188–199. Epub 2003 Sep 19.
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156–1166. Epub 2001 Jul 4.
   PubMed Web of Science ®Google Scholar
• Miller DS. Regulation of ABC transporters at the blood-brain barrier. Clin Pharmacol Ther. 2015;97:395–403. Epub 2015 Feb 12.
   PubMed Web of Science ®Google Scholar
• Smith MW, Gumbleton M. Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies. J Drug Target. 2006;14:191–214. Epub 2006 Jun 17.
   PubMed Web of Science ®Google Scholar
• Kumagai AK, Eisenberg JB, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem. 1987;262:15214–15219. Epub 1987 Nov 5.
   PubMed Web of Science ®Google Scholar
• Katritzky AR, Kuanar M, Slavov S, et al. Correlation of blood-brain penetration using structural descriptors. Bioorg Med Chem. 2006;14:4888–4917.
   PubMed Web of Science ®Google Scholar
• Klepsch F, Vasanthanathan P, Ecker GF. Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors. J Chem Inf Model. 2014;54:218–229. Epub 2013 Sep 21.
   PubMed Web of Science ®Google Scholar
• Palestro PH, Gavernet L, Estiu GL, et al. Docking applied to the prediction of the affinity of compounds to P-glycoprotein. Biomed Res Int. 2014;2014:358425. Epub 2014 Jul 2.
   PubMedGoogle Scholar
• Penzotti JE, Lamb ML, Evensen E, et al. A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem. 2002;45:1737–1740. Epub 2002 Apr 19.
   PubMed Web of Science ®Google Scholar
• Prachayasittikul V, Mandi P, Prachayasittikul S, et al. Exploring the chemical space of P-glycoprotein interacting compounds. Mini Rev Med Chem. 2017;17:1332–1345. Epub 2016 Jan 23.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug and gene targeting to the brain with molecular trojan horses. Nat Rev Drug Discov. 2002;1:131–139. Epub 2002 Jul 18.
   PubMed Web of Science ®Google Scholar
• Blumling Iii JP, Silva GA. Targeting the brain: advances in drug delivery. Curr Pharm Biotechnol. 2012;13:2417–2426. Epub 2012 Sep 29.
   PubMed Web of Science ®Google Scholar
• Wong HL, Chattopadhyay N, Wu XY, et al. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010;62:503–517. Epub 2009 Nov 17.
   PubMed Web of Science ®Google Scholar
• Khalil IA, Kogure K, Akita H, et al. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006;58:32–45. Epub 2006 Mar 2.
   PubMed Web of Science ®Google Scholar
• Lajoie JM, Shusta EV. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613–631. Epub 2014 Oct 24.
   PubMed Web of Science ®Google Scholar
• Dani JA. Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. Int Rev Neurobiol. 2015;124:3–19. Epub 2015 Oct 17.
   PubMed Web of Science ®Google Scholar
• Hogg RC, Raggenbass M, Bertrand D. Nicotinic acetylcholine receptors: from structure to brain function. Rev Physiol Biochem Pharmacol. 2003;147:1–46. Epub 2003 Jun 5.
   PubMed Web of Science ®Google Scholar
• McKay BE, Placzek AN, Dani JA. Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem Pharmacol. 2007;74:1120–1133. Epub 2007 Aug 11.
   PubMed Web of Science ®Google Scholar
• Stokes C, Treinin M, Papke RL. Looking below the surface of nicotinic acetylcholine receptors. Trends Pharmacol Sci. 2015;36:514–523. Epub 2015 Jun 13.
   PubMed Web of Science ®Google Scholar
• Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–w303. Epub 2018 May 23.
   PubMed Web of Science ®Google Scholar
• Eswar N, Eramian D, Webb B, et al. Protein structure modeling with MODELLER. Methods Mol Biol. 2008;426:145–159. Epub 2008 Jun 11.
   PubMedGoogle Scholar
• Daneman R. The blood-brain barrier in health and disease. Ann Neurol. 2012;72:648–672. Epub 2013 Jan 3.
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. 2011;12:169–182. Epub 2011 Feb 19.
   PubMed Web of Science ®Google Scholar
• Liebner S, Dijkhuizen RM, Reiss Y, et al. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 2018;135:311–336. Epub 2018 Feb 8.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19:1584–1596. Epub 2013Dec 7.
   PubMed Web of Science ®Google Scholar
• Bhowmik A, Khan R, Ghosh MK. Blood brain barrier: a challenge for effectual therapy of brain tumors. Biomed Res Int. 2015;2015:320941. Epub 2015 Apr 14.
   PubMed Web of Science ®Google Scholar
• Dowd CF, Halbach VV, Higashida RT. Meningiomas: the role of preoperative angiography and embolization. Neurosurg Focus. 2003;15:E10. Epub 2004 Sep 10.
   PubMedGoogle Scholar
• Groothuis DR, Vriesendorp FJ, Kupfer B, et al. Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann Neurol. 1991;30:581–588. Epub 1991 Oct 1.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109. Epub 2007 Jul 10.
   PubMed Web of Science ®Google Scholar
• Chen R, Smith-Cohn M, Cohen AL, et al. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14:284–297. Epub 2017 Mar 11.
   PubMed Web of Science ®Google Scholar
• Long DM. Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg. 1970;32:127–144. Epub 1970 Feb 1.
   PubMed Web of Science ®Google Scholar
• Luissint AC, Artus C, Glacial F, et al. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9:23. Epub 2012 Nov 13.
   PubMedGoogle Scholar
• Dhawan P, Singh AB, Deane NG, et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest. 2005;115:1765–1776. Epub 2005 Jun 21.
   PubMed Web of Science ®Google Scholar
• Jia W, Lu R, Martin TA, et al. The role of claudin-5 in blood-brain barrier (BBB) and brain metastases (review). Mol Med Rep. 2014;9:779–785. Epub 2013 Dec 25.
   PubMed Web of Science ®Google Scholar
• Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev. 2005;57:883–917. Epub 2005 Apr 12.
   PubMed Web of Science ®Google Scholar
• Khan N, Asif AR. Transcriptional regulators of claudins in epithelial tight junctions. Mediators Inflamm. 2015;2015:219843. Epub 2015 May 8.
   PubMedGoogle Scholar
• Stamatovic SM, Johnson AM, Keep RF, et al. Junctional proteins of the blood-brain barrier: new insights into function and dysfunction. Tissue Barriers. 2016;4:e1154641. Epub 2016 May 4.
   PubMed Web of Science ®Google Scholar
• Runkle EA, Mu D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013;337:41–48. Epub 2013 Jun 8.
   PubMed Web of Science ®Google Scholar
• Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100:323–331. Epub 2000 Aug 31.
   PubMed Web of Science ®Google Scholar
• Lamszus K, Laterra J, Westphal M, et al. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 1999;17:517–530. Epub 1999 Nov 26.
   PubMed Web of Science ®Google Scholar
• van Assema DM, Lubberink M, Rizzu P, et al. Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer’s disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res. 2012;2:57. Epub 2012 Oct 17.
   PubMed Web of Science ®Google Scholar
• Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:179–194. Epub 2000 Jun 6.
   PubMed Web of Science ®Google Scholar
• DeMars KM, Yang C, Hawkins KE, et al. Spatiotemporal changes in P-glycoprotein levels in brain and peripheral tissues following ischemic stroke in rats. J Exp Neurosci. 2017;11:1179069517701741. Epub 2017 May 5.
   Web of Science ®Google Scholar
• Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos. 2014;42:623–631. Epub 2014 Feb 5.
   PubMed Web of Science ®Google Scholar
• Asgharzadeh MR, Barar J, Pourseif MM, et al. Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. Bioimpacts. 2017;7:115–133.
   PubMed Web of Science ®Google Scholar
• Padma VV. An overview of targeted cancer therapy. Biomedicine (Taipei). 2015;5:19. Epub 2015 Nov 29.
   PubMedGoogle Scholar
• Nasiri H, Valedkarimi Z, Aghebati-Maleki L, et al. Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol. 2018;233:6441–6457.
   Web of Science ®Google Scholar
• Srinivasarao M, Low PS. Ligand-targeted drug delivery. Chem Rev. 2017;117:12133–12164. Epub 2017 Sep 13.
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448:39–43. Epub 2007 Jun 19.
   PubMed Web of Science ®Google Scholar
• Zhan C, Yan Z, Xie C, et al. 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery. Mol Pharm. 2010;7:1940–1947. Epub 2010 Oct 23.
   PubMed Web of Science ®Google Scholar
• Banks WA. Peptides and the blood-brain barrier. Peptides. 2015;72:16–19. Epub 2015 Mar 26.
   PubMed Web of Science ®Google Scholar
• Hamilton GS. Antibody-drug conjugates for cancer therapy: the technological and regulatory challenges of developing drug-biologic hybrids. Biologicals. 2015;43:318–332. Epub 2015 Jun 8.
   PubMed Web of Science ®Google Scholar
• Jain N, Smith SW, Ghone S, et al. Current ADC linker chemistry. Pharm Res. 2015;32:3526–3540.
   PubMed Web of Science ®Google Scholar
• Parslow AC, Parakh S, Lee FT, et al. Antibody-drug conjugates for cancer therapy. Biomedicines. 2016;4. Epub 2017 May 26.
   PubMed Web of Science ®Google Scholar
• Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70. Epub 2012 Nov 13.
   PubMed Web of Science ®Google Scholar
• Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol. 2008;26:925.
   PubMed Web of Science ®Google Scholar
• Boiziau C, Nikolski M, Mordelet E, et al. A peptide targeting inflammatory CNS lesions in the EAE rat model of multiple sclerosis. Inflammation. 2018. Epub 2018 Mar 9.
   PubMed Web of Science ®Google Scholar
• Barar J, Omidi Y. Dysregulated pH in tumor microenvironment checkmates cancer therapy. Bioimpacts. 2013;3:149–162.
   PubMedGoogle Scholar
• Omidi Y, Barar J. Targeting tumor microenvironment: crossing tumor interstitial fluid by multifunctional nanomedicines. Bioimpacts. 2014;4:55–67.
   PubMedGoogle Scholar
• Ackerman ME, Pawlowski D, Wittrup KD. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Mol Cancer Ther. 2008;7:2233–2240. Epub 2008 Jul 23.
   PubMed Web of Science ®Google Scholar
• Hilchie AL, Sharon AJ, Haney EF, et al. Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma. Biochim Biophys Acta. 2016;1858:3195–3204. Epub 2016 Nov 5.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev. 1986;7:314–330. Epub 1986 Aug 1.
   PubMed Web of Science ®Google Scholar
• Georgieva JV, Brinkhuis RP, Stojanov K, et al. Peptide-mediated blood-brain barrier transport of polymersomes. Angew Chem Int Ed Engl. 2012;51:8339–8342. Epub 2012 Jul 13.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cheetham AG, Angacian G, et al. Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv Drug Deliv Rev. 2017;110–111:112–126. Epub 2016 Jul 3.
   PubMed Web of Science ®Google Scholar
• Majumdar S, Siahaan TJ. Peptide-mediated targeted drug delivery. Med Res Rev. 2012;32:637–658. Epub 2010 Sep 4.
   PubMed Web of Science ®Google Scholar
• van Zutphen S, Robillard MS, van der Marel GA, et al. Extending solid-phase methods in inorganic synthesis: the first dinuclear platinum complex synthesised via the solid phase. Chem Commun (Camb). 2003;63:4–5. Epub 2003 Apr 3.
   Google Scholar
• Zhang P, Cheetham AG, Lock LL, et al. Cellular uptake and cytotoxicity of drug-peptide conjugates regulated by conjugation site. Bioconjug Chem. 2013;24:604–613. Epub 2013 Mar 22.
   PubMed Web of Science ®Google Scholar
• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20:122–128.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zuo Z. Impact of transporters and enzymes from blood-cerebrospinal fluid barrier and brain parenchyma on CNS drug uptake. Expert Opin Drug Metab Toxicol. 2018;14:961–972. Epub 2018 Aug 18.
   PubMed Web of Science ®Google Scholar
• Bausback HH, Churchill L, Ward PE. Angiotensin metabolism by cerebral microvascular aminopeptidase A. Biochem Pharmacol. 1988;37:155–160. Epub 1988 Jan 15.
   PubMed Web of Science ®Google Scholar
• Brownson EA, Abbruscato TJ, Gillespie TJ, et al. Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J Pharmacol Exp Ther. 1994;270:675–680. Epub 1994 Aug 1.
   PubMed Web of Science ®Google Scholar
• Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood-brain barrier. Neurorx. 2005;2:44–53. Epub 2005 Feb 18.
   PubMedGoogle Scholar
• Vlieghe P, Lisowski V, Martinez J, et al. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15:40–56. Epub 2009 Nov 3.
   PubMed Web of Science ®Google Scholar
• Ma L, Wang C, He Z, et al. Peptide-drug conjugate:a novel drug design approach. Curr Med Chem. 2017;24:3373–3396. Epub 2017 Apr 11.
   PubMed Web of Science ®Google Scholar
• Barar J, Omidi Y. Surface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer. Bioimpacts. 2014;4:3–14.
   PubMedGoogle Scholar
• Deshayes S, Morris MC, Divita G, et al. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci. 2005;62:1839–1849. Epub 2005 Jun 22.
   PubMed Web of Science ®Google Scholar
• Guo Z, Peng H, Kang J, et al. Cell-penetrating peptides: possible transduction mechanisms and therapeutic applications. Biomed Rep. 2016;4:528–534.
   PubMed Web of Science ®Google Scholar
• Das AT, Harwig A, Berkhout B. The HIV-1 tat protein has a versatile role in activating viral transcription. J Virol. 2011;85:9506–9516.
   PubMed Web of Science ®Google Scholar
• Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57:637–651. Epub 2005 Feb 22.
   PubMed Web of Science ®Google Scholar
• Zhang P, Cheetham AG, Lin Y-A, et al. Self-assembled tat nanofibers as effective drug carrier and transporter. ACS Nano. 2013;7:5965–5977.
   PubMed Web of Science ®Google Scholar
• Yandek LE, Pokorny A, Floren A, et al. Mechanism of the cell-penetrating peptide transportan 10 permeation of lipid bilayers. Biophys J. 2007;92:2434–2444. Epub 2007 Jan 16.
   PubMed Web of Science ®Google Scholar
• Lang R, Gundlach AL, Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther. 2007;115:177–207. Epub 2007 Jul 3.
   PubMed Web of Science ®Google Scholar
• Izabela R, Jarosław R, Magdalena A, et al. Transportan 10 improves the anticancer activity of cisplatin. Naunyn-Schmiedeberg’s Arch Pharmacol. 2016;389:485–497.
   Google Scholar
• Kang MJ, Kim BG, Eum JY, et al. Design of a Pep-1 peptide-modified liposomal nanocarrier system for intracellular drug delivery: conformational characterization and cellular uptake evaluation. J Drug Target. 2011;19:497–505. Epub 2010 Aug 27.
   PubMed Web of Science ®Google Scholar
• Mousavizadeh A, Jabbari A, Akrami M, et al. Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: a systematic review. Colloids Surf B Biointerfaces. 2017;158:507–517. Epub 2017 Jul 25.
   PubMed Web of Science ®Google Scholar
• Gao H, Zhang S, Cao S, et al. Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm. 2014;11:2755–2763.
   PubMed Web of Science ®Google Scholar
• Shao K, Huang R, Li J, et al. Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. J Control Release. 2010;147:118–126. Epub 2010 Jul 9.
   PubMed Web of Science ®Google Scholar
• Huang R, Ma H, Guo Y, et al. Angiopep-conjugated nanoparticles for targeted long-term gene therapy of parkinson’s disease. Pharm Res. 2013;30:2549–2559. Epub 2013 May 25.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ying X, Chen L, et al. Electroresponsive nanoparticles improve antiseizure effect of phenytoin in generalized tonic-clonic seizures. Neurotherapeutics. 2016;13:603–613. Epub 2016 May 4.
   PubMed Web of Science ®Google Scholar
• Wang X, Xiong Z, Liu Z, et al. Angiopep-2/IP10-EGFRvIIIscFv modified nanoparticles and CTL synergistically inhibit malignant glioblastoma. Sci Rep. 2018;8:12827.
   PubMed Web of Science ®Google Scholar
• Huey R, Hawthorne S, McCarron P. The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: a mini review. J Drug Target. 2017;25:379–385. Epub 2016 Sep 2.
   PubMed Web of Science ®Google Scholar
• Oswald M, Geissler S, Goepferich A. Targeting the central nervous system (CNS): a review of rabies virus-targeting strategies. Mol Pharm. 2017;14:2177–2196. Epub 2017 May 19.
   PubMed Web of Science ®Google Scholar
• Barrett GL, Trieu J, Naim T. The identification of leptin-derived peptides that are taken up by the brain. Regul Pept. 2009;155:55–61. Epub 2009 Feb 24.
   PubMedGoogle Scholar
• Thomas FC, Taskar K, Rudraraju V, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res. 2009;26:2486–2494.
   PubMed Web of Science ®Google Scholar
• Costantino L, Gandolfi F, Tosi G, et al. Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release. 2005;108:84–96. Epub 2005 Sep 13.
   PubMed Web of Science ®Google Scholar
• Omidi Y. Smart multifunctional theranostics: simultaneous diagnosis and therapy of cancer. BioImpacts. 2011;1:145–147.
   PubMedGoogle Scholar
• Watanabe S, Inoue A, Nukiwa T, et al. Comparison of gefitinib versus chemotherapy in patients with non-small cell lung cancer with exon 19 deletion. Anticancer Res. 2015;35:6957–6961. Epub 2015 Dec 8.
   PubMed Web of Science ®Google Scholar
• Baird K, Comis LE, Joe GO, et al. Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:1083–1090. Epub 2015 Mar 17.
   PubMed Web of Science ®Google Scholar
• David B, Bsa G. Drug delivery and release systems for targeted tumor therapy. J Pept Sci. 2015;21:186–200.
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang F, Lu A, et al. Linkers having a crucial role in antibody–drug conjugates. Int J Mol Sci. 2016;17:561.
   PubMed Web of Science ®Google Scholar
• Yao H, Jiang F, Lu A, et al. Methods to design and synthesize antibody-drug conjugates (ADCs). Int J Mol Sci. 2016;17:194.
   Web of Science ®Google Scholar
• Choy CJ, Geruntho JJ, Davis AL, et al. Tunable pH-sensitive linker for controlled release. Bioconjug Chem. 2016;27:824–830. Epub 2016 Feb 18.
   PubMed Web of Science ®Google Scholar
• Jin Y, Huang Y, Yang H, et al. A peptide-based pH-sensitive drug delivery system for targeted ablation of cancer cells. Chem Commun. 2015;51:14454–14457.
   PubMed Web of Science ®Google Scholar
• Gillies ER, Goodwin AP, Fréchet JMJ. Acetals as pH-sensitive linkages for drug delivery. Bioconjugate Chem. 2004;15:1254–1263.
   PubMed Web of Science ®Google Scholar
• Vrettos EI, Mező G, Tzakos AG. On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site. Beilstein J Org Chem. 2018;14:930–954.
   PubMed Web of Science ®Google Scholar
• Pramanik P, Halder D, Jana SS, et al. pH-triggered sustained drug delivery from a polymer micelle having the beta-thiopropionate linkage. Macromol Rapid Commun. 2016;37:1499–1506. Epub 2016 Jul 23.
   PubMed Web of Science ®Google Scholar
• Shen WC, Ryser HJ. Cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Biophys Res Commun. 1981;102:1048–1054. Epub 1981 Oct 15.
   PubMed Web of Science ®Google Scholar
• Yang D, Chen W, Hu J. Design of controlled drug delivery system based on disulfide cleavage trigger. J Phys Chem B. 2014;118:12311–12317.
   PubMed Web of Science ®Google Scholar
• Su Y, Hu Y, Du Y, et al. Redox-responsive polymer–drug conjugates based on doxorubicin and chitosan oligosaccharide-g-stearic acid for cancer therapy. Mol Pharm. 2015;12:1193–1202.
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280–9290. Epub 2008 Nov 18.
   PubMed Web of Science ®Google Scholar
• Joseph SC, Blackman BA, Kelly ML, et al. Synthesis, characterization, and biological activity of poly(arginine)-derived cancer-targeting peptides in HepG2 liver cancer cells. J Pept Sci. 2014;20:736–745. Epub 2014 Jun 17.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao M, Feng F, et al. Tunable thioesters as “reduction” responsive functionality for traceless reversible protein PEGylation. J Am Chem Soc. 2013;135:10938–10941.
   PubMed Web of Science ®Google Scholar
• Zhang R, Yang J, Radford DC, et al. FRET Imaging of enzyme-responsive HPMA copolymer conjugate. Macromol Biosci. 2017;17:1–8.
   Web of Science ®Google Scholar
• Caculitan NG, Dela Cruz Chuh J, Ma Y, et al. Cathepsin B is dispensable for cellular processing of cathepsin B-cleavable antibody-drug conjugates. Cancer Res. 2017;77:7027–7037. Epub 2017 Oct 20.
   PubMed Web of Science ®Google Scholar
• Fuselier JA, Sun L, Woltering SN, et al. An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003;13:799–803. Epub 2003 Mar 6.
   PubMed Web of Science ®Google Scholar
• Coin I, Beyermann M, Bienert M. Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences. Nat Protoc. 2007;2:3247–3256. Epub 2007 Dec 15.
   PubMed Web of Science ®Google Scholar
• Blencowe CA, Russell AT, Greco F, et al. Self-immolative linkers in polymeric delivery systems. Polym Chem. 2011;2:773–790.
   Web of Science ®Google Scholar
• Riber CF, Smith AA, Zelikin AN. Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs. Adv Healthc Mater. 2015;4:1887–1890. Epub 2015 Jun 26.
   PubMed Web of Science ®Google Scholar
• Smith G. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985;228:1315–1317.
   PubMed Web of Science ®Google Scholar
• Tohidkia MR, Barar J, Asadi F, et al. Molecular considerations for development of phage antibody libraries. J Drug Target. 2012;20:195–208.
   PubMed Web of Science ®Google Scholar
• Zhao A, Tohidkia MR, Siegel DL, et al. Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Crit Rev Biotechnol. 2016;36:276–289.
   PubMed Web of Science ®Google Scholar
• Bazan J, Calkosinski I, Gamian A. Phage display–a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother. 2012;8:1817–1828.
   PubMed Web of Science ®Google Scholar
• Hamzeh-Mivehroud M, Alizadeh AA, Morris MB, et al. Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov Today. 2013;18:1144–1157.
   PubMed Web of Science ®Google Scholar
• Jafari B, Hamzeh-Mivehroud M, Moosavi-Movahedi AA, et al. Identification of novel single-domain antibodies against FGF7 using phage display technology. SLAS Discov. 2018;23:193–201. Epub 2017 Aug 30.
   PubMed Web of Science ®Google Scholar
• Jalilzadeh-Razin S, Mantegi M, Tohidkia MR, et al. Phage antibody library screening for the selection of novel high-affinity human single-chain variable fragment against gastrin receptor: an in silico and in vitro study. Daru. 2019. Epub 2019 Jan 5.
   PubMed Web of Science ®Google Scholar
• Coomber DW. Panning of antibody phage-display libraries. Standard protocols. Methods Mol Biol. 2002;178:133–145. Epub 2002 Apr 24.
   PubMedGoogle Scholar
• Bakhshinejad B, Karimi M, Khalaj-Kondori M. Phage display: development of nanocarriers for targeted drug delivery to the brain. Neural Regen Res. 2015;10:862–865. Epub 2015 Jul 23.
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308–316. Epub 2009 Feb 4.
   PubMed Web of Science ®Google Scholar
• Malcor JD, Payrot N, David M, et al. Chemical optimization of new ligands of the low-density lipoprotein receptor as potential vectors for central nervous system targeting. J Med Chem. 2012;55:2227–2241. Epub 2012 Jan 20.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodríguez JA, et al. Transferrin receptors and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820:291–317.
   PubMed Web of Science ®Google Scholar
• Lee JH, Engler JA, Collawn JF, et al. Receptor-mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem. 2001;268:2004–2012. Epub 2001 Mar 30.
   PubMedGoogle Scholar
• Prades R, Guerrero S, Araya E, et al. Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor. Biomaterials. 2012;33:7194–7205. Epub 2012 Jul 17.
   PubMed Web of Science ®Google Scholar
• Prades R, Oller-Salvia B, Schwarzmaier SM, et al. Applying the retro-enantio approach to obtain a peptide capable of overcoming the blood-brain barrier. Angew Chem Int Ed Engl. 2015;54:3967–3972. Epub 2015 Feb 5.
   PubMed Web of Science ®Google Scholar
• Staquicini FI, Ozawa MG, Moya CA, et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J Clin Invest. 2011;121:161–173. Epub 2010 Dec 25.
   PubMed Web of Science ®Google Scholar
• Parton RG. Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J Histochem Cytochem. 1994;42:155–166. Epub 1994 Feb 1.
   PubMed Web of Science ®Google Scholar
• Li J, Feng L, Fan L, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32:4943–4950. Epub 2011 Apr 8.
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Cao S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33:5115–5123. Epub 2012 Apr 10.
   PubMed Web of Science ®Google Scholar
• Zhang C, Wan X, Zheng X, et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of alzheimer’s disease mice. Biomaterials. 2014;35:456–465. Epub 2013 Oct 9.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Y, Zhang T, et al. Development of bioactive materials for glioblastoma therapy. Bioact Mater. 2016;1:29–38.
   PubMed Web of Science ®Google Scholar
• Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia. 2011;59:1169–1180.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Dhimolea E. Brentuximab vedotin. mAbs. 2012;4:458–465.
   PubMed Web of Science ®Google Scholar
• Traynor K. Ado-trastuzumab emtansine approved for advanced breast cancer. Am J Health Syst Pharm. 2013;70:562.
   PubMed Web of Science ®Google Scholar